Cytokinetics, Incorporated
NASDAQ:CYTKBiotechnology
+$2.90 today
- Market cap
- $7.15B
- Beta
- 0.43
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$6.73
Volume 1.59M
Average 2.37M
CYTK Other Financing Activities
Financing cash flows not reported separately.
Cytokinetics, IncorporatedNASDAQ: CYTK
Other Financing Activities · Q2 FY2026 · quarter ended Jun 2026
Other financing activities turns negative
Q2 FY2026 other financing activities was -$1.7M, compared with $74.49M a year earlier. Trailing-twelve-month other financing activities was -$79.48M.
Context
- Other financing activities amounted to 2.8% of revenue in FY2025, down 1260.5 pp from a year earlier.
- Other financing activities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other financing activities holds near -$1.7M or moves back toward the trailing-twelve-month quarterly average of -$19.87M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (2.47M) USD
- Year-over-year change
- -101.1%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.47M) | -101.1% |
| FY2024 | 2024-12-31 | 233.39M | +302.8% |
| FY2023 | 2023-12-31 | 57.94M | -64.7% |
| FY2022 | 2022-12-31 | 163.96M | +1967.4% |
| FY2021 | 2021-12-31 | 7.93M | — |
Other Financing Activities vs competitors
How CYTK compares with its peers on the latest reported figures
- CYTK's LTM Jun 2026 other financing activities of $79.48M is the largest of the 3 companies compared; the peer median is $21.08M.
- Other financing activities amounts to 112.0% of revenue for CYTK, versus a peer median of 206.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $79.48M | -208.4% | — | 112.0% | |
| FY2025 | $42.57M | — | — | 228.7% | |
| LTM Mar 2026 | $415K | — | — | 184.4% | |
| — | — | — | — | — | |
| Peer median (excluding CYTK) | $21.08M | — | — | 206.6% | |
Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (215.31M) | (388.96M) | (526.24M) | (589.53M) | (784.96M) |
| Depreciation & Amortization | 2.28M | 5.81M | 11.89M | 9.53M | 10.13M |
| Deferred Income Tax | 2.84M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 26.83M | 47.85M | 72.07M | 97.84M | 112.29M |
| Change in Working Capital | 8.46M | (24.7M) | 3.09M | 35.66M | (35.63M) |
| Accounts Receivables | (47.4M) | 56.67M | (1.14M) | (15.37M) | (1.11M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.06M | 4.52M | (3.48M) | (4.48M) | 2.66M |
| Other Working Capital | 54.8M | (85.9M) | 7.71M | 55.51M | (37.18M) |
| Other Non-Cash Items | 32.38M | 60.48M | 24.87M | 50.6M | 188.16M |
| Operating Cash Flow | (142.52M) | (299.52M) | (414.33M) | (395.89M) | (510.01M) |
| Capital Expenditures | (48.87M) | (11.34M) | (1.42M) | (3.91M) | (24.81M) |
| Acquisitions (Net) | 98.91M | 250.8M | 0 | 0 | 0 |
| Purchases of Investments | (525.04M) | (855.39M) | (635.21M) | (1.29B) | (1.06B) |
| Sales of Investments | 426.14M | 604.59M | 875.88M | 744.23M | 1.11B |
| Other Investing Activities | (98.91M) | (250.8M) | 0 | 0 | (5M) |
| Investing Cash Flow | (147.78M) | (262.13M) | 239.25M | (553.1M) | 16.67M |
| Debt Repayment | 0 | 334.66M | (858K) | (9.62M) | 490.95M |
| Common Stock Issued | 312.05M | 17.54M | 164.23M | 706.84M | 35.98M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.93M | 163.96M | 57.94M | 233.39M | (2.47M) |
| Financing Cash Flow | 319.98M | 516.17M | 221.32M | 930.61M | 524.46M |
| Effect of Forex Changes | 0 | 0 | (20K) | 209K | (715K) |
| Net Change in Cash | 29.68M | (45.48M) | 46.22M | (18.17M) | 30.4M |
| Free Cash Flow | (191.39M) | (310.85M) | (415.75M) | (399.8M) | (534.82M) |
Cytokinetics, Incorporated
NASDAQ:CYTK
Intrinsic Alpha fair value
Locked
Current Price
$51.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.